The FDA plans to generally require only one clinical study, rather than the traditional two, for medical product approvals, according to Commissioner Marty Makary, STAT’s Lizzy Lawrence reports. While two trials will still be required in certain cases, the default approach will shift to a single pivotal study, reflecting current industry practices, according to the report. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY), while companies conducting drug trials on behalf of pharmaceutical companies include Icon (ICLR), Iqvia (IQV), and Medpace (MEDP).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- FDA to reduce number of trials required for drug approvals, STAT reports
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- Vaccine committee considers changes to childhood schedule, NY Times reports
- Johnson & Johnson price target raised to $197 from $176 at Barclays